Avri Havron
Directeur/Bestuurslid bij Active P Ltd.
Vermogen: 257 885 $ op 30-04-2024
Profiel
Avri Havron is currently a Director at Active P Ltd.
Previously, he worked as a Director at AngioB Ltd.
and as a Principal at Modigen Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2023 | 177 852 ( 0.96% ) | 257 885 $ | 30-04-2024 |
Actieve functies van Avri Havron
| Bedrijven | Functie | Begin |
|---|---|---|
Active P Ltd.
 Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Directeur/Bestuurslid | 03-03-2010 |
Eerdere bekende functies van Avri Havron
| Bedrijven | Functie | Einde |
|---|---|---|
| Modigen Ltd. | Corporate Officer/Principal | - |
AngioB Ltd.
 AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
AngioB Ltd.
AngioB Ltd. Medical SpecialtiesHealth Technology AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel | Health Technology |
Active P Ltd.
Active P Ltd. Pharmaceuticals: MajorHealth Technology Active P Ltd. develops proprietary oral available peptide drugs to treat diabetes. The company was founded by Shmulik Hess, Chaim Gilon, and Amnon Hoffman on September 10, 2008 and is headquartered in Kiryat Shmona, Israel. | Health Technology |
| Modigen Ltd. |
